News

Goldman Sachs Remains Positive as Eli Lilly (LLY) Expands Obesity Drug Pipeline

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...

Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...
GlobalData on MSN17h

Eli Lilly eyes orforglipron approval after Phase III diabetes trial success

Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...
Fierce Pharma14h

Facing pressure from Novartis, Eli Lilly trots out Verzenio patient survival win in early breast cancer

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

Stock Movers: Eli Lilly, EchoStar, UnitedHealth

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The bear case on Eli Lilly has played out, says only firm to have called it a sell

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

How the top pharma companies are doing as Eli Lilly is S&P 500’s biggest gainer

Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that ...

Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data

Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving ...